CytoSorbents Corporation (CTSO) is a fast-paced, established public company that operates in the field of critical care immunotherapy. Broadly, the company’s work focuses on preventing or treating organ failure in life-threatening illnesses. Headquartered in Monmouth Junction, New Jersey, CytoSorbents commercializes innovative medical technologies, primarily CytoSorb, which represents a new, highly promising standard of care in immunotherapy. CytoSorbents Corporation is traded as CTSO on the NASDAQ exchange.
CytoSorb, the company’s main product, is a blood purification technology. It can be used in the intensive care unit to remove cytokines, which are proteins released by cells and can cause inflammation. By reducing the cytokine storm, CytoSorb supports the body's immune response and helps to prevent organ failure. It has been used in more than 111,000 human treatments to date.
CytoSorbents' mission is to save lives through the use of its novel CytoSorb blood purification technology. Aiming to transform therapy in critical illnesses, the technology represents a paradigm shift in treating severe inflammatory conditions driven by the body's out-of-control response to infection, trauma or other severe conditions (acute illnesses), such as sepsis, burn injury, trauma, lung injury, and pancreatitis.
The company has also launched other immunotherapy products, including HemoDefend, ContrastSorb, DrugSorb, and others. These products are focused on blood purification, drug overdose, and poison treatment, and organ transplantation support, respectively.
CytoSorbents conducts business worldwide, with a focus on North America, Europe, and Asia. It has numerous partnerships and collaborations with leading global companies, universities, and research institutions, aiming to create value not only for its clients in the healthcare sector, but also for its shareholders.
Since its inception, CytoSorbents has successfully raised close to $100M in funding, which testifies to the potential and effectiveness of its technology and solidifies its position as one of the leading critical care therapies. Its operational growth and sphere influence have demonstrated the ability of the company to respond to real-world issues in healthcare. The continuous research, innovative approaches, and focus on saving lives have established CytoSorbents Corporation as a pioneer in their field, with the potential to revolutionize immunotherapy for critical care patients.